1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Uterine Cancer - Pipeline Review, H2 2014

Uterine Cancer - Pipeline Review, H2 2014

  • September 2014
  • -
  • Global Markets Direct
  • -
  • 66 pages

Uterine Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Uterine Cancer - Pipeline Review, H2 2014’, provides an overview of the Uterine Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uterine Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uterine Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Uterine Cancer - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Uterine Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Uterine Cancer - Overview 7
Pipeline Products for Uterine Cancer - Comparative Analysis 8
Uterine Cancer - Therapeutics under Development by Companies 9
Uterine Cancer - Therapeutics under Investigation by Universities/Institutes 10
Uterine Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Uterine Cancer - Products under Development by Companies 14
Uterine Cancer - Products under Investigation by Universities/Institutes 15
Uterine Cancer - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Azaya Therapeutics Incorporated 17
EndoCeutics, Inc. 18
Karyopharm Therapeutics, Inc. 19
Uterine Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
acolbifene hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
pazopanib hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
selinexor - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
docetaxel liposomal - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
MVX-ONCO-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Adva-27a - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Small Molecule to Inhibit GARFT for Oncology - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Uterine Cancer - Recent Pipeline Updates 48
Uterine Cancer - Dormant Projects 60
Uterine Cancer - Product Development Milestones 61
Featured News and Press Releases 61
Jun 09, 2014: Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells 61
Aug 12, 2013: Advanomics wins research grant for cancer drug candidate 61
Jun 19, 2013: Sunshine Biopharma's Anticancer Drug Candidate Adva-27a Is Unaffected By Recent Supreme Court Ruling On Patentability Of Human Genes 62
Jan 15, 2013: Advanomics Files New Patent Application For Multidrug Resistance Adva-27a Anticancer Compound 62
Dec 10, 2012: Sunshine Biopharma Completes Another IND-enabling Study Of Adva-27a 62
Jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of ATI-1123 63
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables

Number of Products under Development for Uterine Cancer, H2 2014 7
Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Uterine Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 16
Uterine Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 17
Uterine Cancer - Pipeline by EndoCeutics, Inc., H2 2014 18
Uterine Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Uterine Cancer Therapeutics - Recent Pipeline Updates, H2 2014 48
Uterine Cancer - Dormant Projects, H2 2014 60

List of Figures

Number of Products under Development for Uterine Cancer, H2 2014 7
Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Target, H2 2014 21
Number of Products by Stage and Top 10 Target, H2 2014 22
Number of Products by Top 10 Mechanism of Action, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 25
Number of Products by Top 10 Route of Administration, H2 2014 27
Number of Products by Stage and Top 10 Route of Administration, H2 2014 28
Number of Products by Top 10 Molecule Type, H2 2014 29
Number of Products by Stage and Top 10 Molecule Type, H2 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US and South Korea

  • November 2016
    2 pages
  • Cancer  

  • United States  

    South Korea  

View report >

Therapy Market in the UK

  • November 2016
    11 pages
  • Therapy  

  • United Kingdom  

View report >

Related Market Segments :

Cancer
Breast Cancer
Lymphoma
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.